According to the results of a new study, in the real-world setting ibrutinib treatment for chronic lymphocytic leukemia (CLL) had positive effects on patients’ health-related quality of life (HRQOL) and treatment satisfaction compared with other therapies, regardless of the line of therapy.
Murali Sundaram, MBA, PhD, of Janssen Scientific Affairs in Horsham, Pennsylvania, and colleasuges from Janssen Global Services in Raritan, New Jersey, and Northwell Health Cancer Institute in New Hyde Park, New York, published their findings in an abstract associated with the National Comprehensive Cancer Network (NCCN) 2020 Annual Conference, which was postponed in response to the coronavirus disease 2019 (COVID-19) pandemic.
The investigators sought to describe HRQOL and treatment satisfaction of ibrutinib-treated patients with CLL in the real-world setting. Their results comprise the second part of a 2-part study. The first part used an online survey to assess HRQOL and treatment satisfaction data from a US panel of real-world patients with CLL who were not treated with ibrutinib (64 treatment naive; 36 first-line; and 38 second-line or higher).
The second part of the study included patients with CLL treated with ibrutinib for at least 6 months. The survey was conducted via phone; respondents provided demographic and clinical information and completed the Functional Assessment of Cancer Therapy-General (FACT-G), FACT-Leukemia, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and Cancer Therapy Satisfaction Questionnaire (CTSQ).
For the second part of the study, an interim analysis of 23 ibrutinib-treated patients was conducted; more than 60% of the participants were male and more than 87% were Caucasian. Of those patients, 10 patients received ibrutinib as first-line treatment, while 13 patients received ibrutinib as second-line or higher treatment. The average age was 67.4 ± 7.1 years. The average treatment duration with ibrutinib was 25.6 ± 14.1 months. The authors noted that the participants from the first part of the study were younger and had a more even distribution of the sexes (~50% female).
Compared with data from the first part of the study, the authors observed medium to large positive effects in the ibrutinib-treated group for most measures, including FACT-G (total score: ibrutinib-treated, 89.2 ± 11.1; treatment naive, 75.8 ± 22.6; other first-line treatment, 61.3 ± 21.8; other second-line treatment or higher 61.7 ± 20.7), FACT-Leukemia (ibrutinib-treated, 139.9 ± 19.1; treatment naive, 121.8 ± 35.9; other first-line treatment, 101.4 ± 36.3; other second-line treatment or higher, 99.1 ± 33.2), and FACIT-Fatigue (ibrutinib-treated, 39.9 ± 10.1; treatment naive, 35.5 ± 14.4; other first-line treatment, 29.5 ± 12.9; other second-line treatment or higher, 28.7 ± 13.4).
According to the authors the ibrutinib-treated patients scored higher on all CTSQ domain scores compared to the patients treated with other CLL therapies.
Disclosures: Some authors have declared affiliations with the pharmaceutical industry. Please refer to the original study for a full list of disclosures
Sundaram M, Deering KL, Sharma D, Harshaw Q, Trudeau J, Barrientos JC. HSR20-107: Health-Related Quality of Life and Treatment Satisfaction in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Compared to a Reference Group on Other CLL Treatments in a Real-World US Cross-Sectional Study. J Natl Compr Canc Netw. 2020;18 (3.5):HSR20-107-HSR20-107.